ATE173544T1 - Parvovirusrezeptoren und verfahren zur ihrer verwendung - Google Patents

Parvovirusrezeptoren und verfahren zur ihrer verwendung

Info

Publication number
ATE173544T1
ATE173544T1 AT94912271T AT94912271T ATE173544T1 AT E173544 T1 ATE173544 T1 AT E173544T1 AT 94912271 T AT94912271 T AT 94912271T AT 94912271 T AT94912271 T AT 94912271T AT E173544 T1 ATE173544 T1 AT E173544T1
Authority
AT
Austria
Prior art keywords
parvovirus
methods
binding
sample
receptor
Prior art date
Application number
AT94912271T
Other languages
English (en)
Inventor
Neal S Young
Kevin E Brown
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE173544T1 publication Critical patent/ATE173544T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AT94912271T 1993-03-22 1994-03-22 Parvovirusrezeptoren und verfahren zur ihrer verwendung ATE173544T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/034,132 US5449608A (en) 1993-03-22 1993-03-22 Parvovirus B19 receptor and parvovirus B19 detection

Publications (1)

Publication Number Publication Date
ATE173544T1 true ATE173544T1 (de) 1998-12-15

Family

ID=21874512

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94912271T ATE173544T1 (de) 1993-03-22 1994-03-22 Parvovirusrezeptoren und verfahren zur ihrer verwendung

Country Status (8)

Country Link
US (1) US5449608A (de)
EP (1) EP0690990B1 (de)
JP (1) JPH08511865A (de)
AT (1) ATE173544T1 (de)
AU (1) AU6449694A (de)
CA (1) CA2158564A1 (de)
DE (1) DE69414700D1 (de)
WO (1) WO1994022014A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005538A1 (en) * 1988-11-14 1990-05-31 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Parvovirus capsids
WO1996041020A1 (en) * 1995-06-07 1996-12-19 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
JPH0910000A (ja) * 1995-06-26 1997-01-14 Nippon Sekijiyuujishiya ヒトパルボウイルスの検出方法及びそのための試薬
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US20040086528A1 (en) * 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
US6528098B2 (en) * 1996-10-22 2003-03-04 Advanced Viral Research Corp. Preparation of a therapeutic composition
US5973128A (en) * 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
US6268349B1 (en) * 1997-04-15 2001-07-31 Advanced Viral Research Corp. Method for treating B19 parvovirus infections
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
AU2002318450B2 (en) 2001-06-28 2007-11-22 Grifols Worldwide Operations Limited Diagnostic assays for parvovirus B19
AU2002323520B2 (en) * 2001-08-31 2008-02-21 Gen-Probe Incorporated Assay for detection of human parvovirus B19 nucleic acid
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
US20060057643A1 (en) * 2004-09-10 2006-03-16 Mccarthy Laurence R Methods and compositions for detecting erythrovirus genotypes
AU2005332686B2 (en) * 2005-06-03 2012-09-27 Ohr Pharmaceutical, Inc. Methods for providing palliative care with AVR118
CN106048082A (zh) * 2007-06-14 2016-10-26 俄克拉荷马州大学评议会 包含犬细小病毒遗传性变体的疫苗
US8227583B2 (en) 2007-06-14 2012-07-24 The Board Of Regents For Oklahoma State University Vaccines containing canine parvovirus genetic variants
US8980545B2 (en) 2008-03-20 2015-03-17 Blood Systems, Inc. Divergent picornavirus: cosavirus
CA2756659A1 (en) 2009-02-26 2010-09-02 Gen-Probe Incorporated Assay for detection of human parvovirus nucleic acid
WO2013012708A1 (en) 2011-07-15 2013-01-24 Gen-Probe Incorporated Compositions and method for detecting human parvovirus nucleic acid and for detecting hepatitis a virus nucleic acids in single-plex or multiplex assays

Also Published As

Publication number Publication date
JPH08511865A (ja) 1996-12-10
EP0690990B1 (de) 1998-11-18
EP0690990A1 (de) 1996-01-10
WO1994022014A1 (en) 1994-09-29
US5449608A (en) 1995-09-12
AU6449694A (en) 1994-10-11
CA2158564A1 (en) 1994-09-29
DE69414700D1 (de) 1998-12-24

Similar Documents

Publication Publication Date Title
ATE173544T1 (de) Parvovirusrezeptoren und verfahren zur ihrer verwendung
ATE377657T1 (de) Serpin-arzneistoffe zur behandlung einer hiv- infektion und verfahren zu deren verwendung
PL374311A1 (en) Methods for purifying protein
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
ATE171472T1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
WO2002010764A3 (en) SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY
DE60039752D1 (de) Herstellung tetravalenter antikörper
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
DE69520149D1 (de) Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen
ATE287948T1 (de) Plasmide dna reinigung durch peg-fällung und säulen-chromatographie
ATE186900T1 (de) Verfahren zur aeroben, weitergehenden biologischen reinigung von abwässern
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE153704T1 (de) Anti-t-zell rezeptordeterminanten zur behandlung von autoimmunkrankheiten
BR9916209A (pt) Cadeia de receptor de citocina
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
ATE259818T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
MXPA02005236A (es) Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
DE69701458D1 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
DE69507017D1 (de) Cai-resistenzproteine kodierende dna, und ihre verwendung
DE69725100D1 (de) Verfahren und Satz zur Prüfung der Drogenempfindlichkeit von Mikroben, sowie Verfahren und Satz zur Missung der minimumhemmenden Konzentration von Mikroorganismen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties